Table 1.
Chemokine Receptor | Roles in tumor development/progression | Clinical association | Cohort details | Statistical analyses | References |
---|---|---|---|---|---|
CCR4 | Favor tumor cell viability, migration, primary tumor growth, and brain metastases formation | Not known | In vitro and preclinical models | (37) | |
CCR6 | Enhanced tumor cell migration, proliferation, tumor growth, and lung metastasis formation | Not associated with patient outcome* | 40 primary melanomas | Log-rank and Cox regression | (38) |
CCR7 | Associated with regional lymph node metastases | Poor prognosis | Preclinical model and 38 primary human samples | Log rank test—P = 0.009 | (39, 40) |
CCR9 | Expressed on tumor cells localized in the small intestine–Sensitive to CCL25 stimulation | Not associated with patient outcome* or not assessed | 38 primary samples | Log rank test | (40–42) |
CCR10 | Associated with an increase of regional lymph node metastases, metastatic sentinel lymph node, thickening of primary lesions and poor T cell density | Shorter progression free survival | 40 primary lesions and 38 primary melanoma samples | Spearman correlation and Log rank test–P = 0.002 | (40, 43, 44) |
CXCR3 | Associated with thick primary lesions, the absence of lymphocytic infiltration and the presence of distant metastases—Increase in cell adhesion, migration, and invasion of CXCR3 expressing melanoma cells lines upon stimulation. | Not associated with patient outcome* | Primary melanomas and 9 Lymph node metastases | χ2, Mann-Whitney U and Kruskal Wallis tests—Log-rank test and Cox regression | (45–48) |
CXCR4 | Associated with the presence of ulceration, thicker lesions—Induce tumor cell proliferation, migration, and invasion—Associated with liver and lung metastases | Reduced disease-free and overall survival | Primary melanomas and metastatic samples | χ2 2-sided test—Log-rank test and Cox regression | (47, 49–52) |
Complementary analyses on larger cohorts are warranted.